Treatment for intermediate and high-risk prostate cancer: Controversial issues and the role of hyperthermia

References

• D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998; 41: 491–500
   PubMed Web of Science ®Google Scholar
• Anscher MS, Samulski TV, Dodge R, Prosnitz LR, Dewhirst MW. Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997; 37: 1059–1065
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103–106
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al. EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009;360:2516–2527
   Google Scholar
• Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013–1021
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285–1290
   PubMed Web of Science ®Google Scholar
• Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, et al. Radiation Therapy Oncology Group. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972–3978
   Google Scholar
• D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation versus radiation alone for prostate cancer: A randomized trial. JAMA 2008; 299: 289–295
   PubMed Web of Science ®Google Scholar
• Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, et al. Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841–850
   Google Scholar
• McGowan DG, Hunt D, Jones CU, Amin M, Leibenhaut MH, Husian SM, Rotman M, Souhami L, Sandler H, Shipley WU. Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA ≤20: Initial results of RTOG 94-08. Int J Radiat Oncol Biol Phys 2010; 77: 1
   Web of Science ®Google Scholar
• Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 1097–1105
   PubMed Web of Science ®Google Scholar
• Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005; 61: 695–701
   PubMed Web of Science ®Google Scholar
• Michalski JM, Bae K, Roach M, Markoe AM, Sandler HM, Ryu J, Parliament MB, Straube W, Valicenti RK, Cox JD. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 2010; 76: 14–22
   PubMed Web of Science ®Google Scholar
• Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010; 303: 1046–1053
   PubMed Web of Science ®Google Scholar
• Roach M, III, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, et al., Radiation Therapy Oncology Group 9413. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003;21:1904–1911
   Google Scholar
• Kampinga HH, Dikomey E. Hyperthermic radiosensitization: Mode of action and clinical relevance. Int J Radiat Biol 2001; 77: 399–408
   PubMed Web of Science ®Google Scholar
• Ryu S, Brown SL, Kim SH, Khil MS, Kim JH. Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 1996; 34: 133–138
   PubMed Web of Science ®Google Scholar
• Kaver I, Koontz WW, Jr, Wilson JD, Guice JM, Ware JL. The effect of radiation therapy and hyperthermia on a human prostatic carcinoma cell line grown in athymic nude mice. J Urol 1991; 145: 654–656
   PubMed Web of Science ®Google Scholar
• Peschke P, Hahn EW, Wenz F, Lohr F, Braunschweig F, Wolber G, Zuna I, Wannenmacher M. Differential sensitivity of three sublines of the rat Dunning prostate tumor system R3327 to radiation and/or local tumor hyperthermia. Radiat Res 1998; 150: 423–430
   PubMed Web of Science ®Google Scholar
• Pajonk F, Van Ophoven A, Mc Bride WH. Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Research 2005; 65: 4836–4843
   PubMed Web of Science ®Google Scholar
• Tsukada T, Inoue M, Tachibana S, Nakai Y, Takebe H. An androgen receptor mutation causing androgen resistance in undervirilized male syndrome. J Clin Endocrinol Metab 1994; 79: 1202–1207
   PubMed Web of Science ®Google Scholar
• Hurwitz MD, Kaplan ID, Hansen JL, Prokopios-Davos S, Topulos GP, Wishnow K, Manola J, Bornstein BA, Hynynen K. Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile. Int J Hyperthermia 2005; 21: 649–656
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, De Leeuw AA, Raaymakers BW, Van Moorselaar RJ, Hofman P, Lagendijk JJ, Battermann JJ. Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: Preliminary results. BJU Int 2004; 93: 36–41
   PubMed Web of Science ®Google Scholar
• Kaplan I, Kapp DS, Bagshaw MA. Secondary external-beam radiotherapy and hyperthermia for local recurrence after 125-iodine implantation in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1991; 20: 551–554
   PubMed Web of Science ®Google Scholar
• Kalapurakal JA, Pierce M, Chen A, Sathiaseelan V. Efficacy of irradiation and external hyperthermia in locally advanced, hormone-refractory or radiation recurrent prostate cancer: A preliminary report. Int J Radiat Oncol Biol Phys 2003; 57: 654–664
   PubMed Web of Science ®Google Scholar
• Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984; 10: 787–790
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 2008; 179: 1368–1373
   PubMed Web of Science ®Google Scholar
• Tilly W, Gellermann J, Graf R, Hildebrandt B, Weissbach L, Budach V, Felix R, Wust P. Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol 2005; 181: 35–41
   PubMed Web of Science ®Google Scholar
• Algan O, Fosmire H, Hynynen K, Dalkin B, Cui H, Drach G, Stea B, Cassady JR. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma. Cancer 2000; 89: 399–403
   PubMed Web of Science ®Google Scholar
• Fosmire H, Hynynen K, Drach GW, Stea B, Swift P, Cassady JR. Feasibility and toxicity of transrectal ultrasound hyperthermia in the treatment of locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993; 26: 253–259
   PubMed Web of Science ®Google Scholar
• American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035–1041.
   Google Scholar
• Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, Hynynen K, Kaplan ID, Hyperthermia combined with radiation in treatment of locally advanced prostate cancer: Long-term results of DFCI 94-153. Cancer 2010, in press
   Google Scholar
• Maluta S, Dall’Oglio S, Romano M, Marciai N, Pioli F, Giri MG, Benecchi PL, Comunale L, Porcaro AB. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: Preliminary results of a prospective phase II study. Int J Hyperthermia 2007; 23: 451–456
   PubMed Web of Science ®Google Scholar
• Prionas SD, Kapp DS, Goffinet DR, Ben-Yosef R, Fessenden P, Bagshaw MA. Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994; 28: 151–162
   PubMed Web of Science ®Google Scholar
• Deger S, Taymoorian K, Boehmer D, Schink T, Roigas J, Wille AH, Budach V, Wernecke KD, Loening SA. Thermoradiotherapy using interstitial self-regulating thermoseeds: An intermediate analysis of a phase II trial. Eur Urol 2004; 45: 574–579
   PubMed Web of Science ®Google Scholar
• Deger S, Boehmer D, Türk I, Roigas J, Wernecke KD, Wiegel T, Hinkelbein W, Dinges S, Budach V, Loening SA. High dose rate brachytherapy of localized prostate cancer. Eur Urol 2002; 41: 420–426
   PubMed Web of Science ®Google Scholar
• Bruns F, Franzki C, Wegener G, Karstens JH. Definitive conformal radiotherapy for localized high-risk prostate cancer: A long-term follow-up study with PSA course. Anticancer Res 2007; 27: 1847–1851
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243–1252
   PubMed Web of Science ®Google Scholar
• Laverdière J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004; 171: 1137–1140
   PubMed Web of Science ®Google Scholar
• Zagars GK, Johnson DE, Von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: Long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988; 14: 1085–1091
   PubMed Web of Science ®Google Scholar
• D’Amico AV. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. J Clin Oncol 2007; 25: 8–9
   PubMed Web of Science ®Google Scholar
• Descazeaud A, Zerbib M, Hofer MD, Chaskalovic J, Debré B, Peyromaure M. Evolution of health-related quality of life two to seven years after retropubic radical prostatectomy: Evaluation by UCLA prostate cancer index. World J Urol 2005; 23: 257–262
   PubMed Web of Science ®Google Scholar
• Moinpour CM, Hayden KA, Unger JM, Thompson Jr IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, et al. Southwest Oncology Group. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008;26:112–120
   Google Scholar
• Siglin J, Kubicek GJ, Leiby B, Valicenti RK. Time of decline in sexual function after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 76: 31–35
   PubMed Web of Science ®Google Scholar
• Van Vulpen M, De Leeuw JRJ, van Gellekom MPR, van der Hoeven J, De Graeff A, van Moorselaar RJA, van der Tweel I, Hofman P, Lagendijk JJW, Batterman JJ. A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia. Int J Hyperthermia 2003; 19: 402–413
   PubMed Web of Science ®Google Scholar
• Gacci M, Simonato A, Masieri L, Gore JL, Lanciotti M, Mantella A, Rossetti MA, Serni S, Varca V, Romagnoli A, et al. Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy. Health Qual Life Outcomes 2009; 7: 94–101
   PubMed Web of Science ®Google Scholar